News
Video
Researchers Say CAEL-101 is an Effective Amyloid Light Chain Amyloidosis Treatment
Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis.
Pharmacy Times® interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis, which was presented at the 62nd American Society of Hematology Annual Meeting & Exposition.
The full conversation can be found in the video above.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
